Evolent Health (EVH)
(Real Time Quote from BATS)
$28.45 USD
-0.81 (-2.77%)
Updated Apr 25, 2024 10:18 AM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Evolent Health (EVH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$44.86 | $63.00 | $34.00 | 53.32% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Evolent Health comes to $44.86. The forecasts range from a low of $34.00 to a high of $63.00. The average price target represents an increase of 53.32% from the last closing price of $29.26.
Analyst Price Targets (14)
Broker Rating
Evolent Health currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.21 a month ago based on 14 recommendations.
Of the 15 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 86.67% and 6.67% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 7.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 12 | 12 | 12 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.21 | 1.21 | 1.21 | 1.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/28/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
3/1/2024 | Stephens | Jeffrey Garro | Strong Buy | Strong Buy |
2/26/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/23/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
2/23/2024 | JMP Securities | Constantine Kyriakos Davides | Strong Buy | Strong Buy |
1/9/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1/7/2024 | BTIG | David M Larsen | Strong Buy | Strong Buy |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.21 |
# of Recs in ABR | 15 |
Average Target Price | $44.86 |
LT Growth Rate | NA |
Industry | Internet - Software |
Industry Rank by ABR | 57 of 252 |
Current Quarter EPS Est: | 0.21 |